These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer. Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036 [TBL] [Abstract][Full Text] [Related]
7. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related]
8. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer. Sharifi N Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793 [TBL] [Abstract][Full Text] [Related]
9. [New generation of androgen receptor antagonist in castration resistant prostate cancer]. Uemura H Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352 [TBL] [Abstract][Full Text] [Related]
10. Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies. Limonta P; Manea M Cancer Treat Rev; 2013 Oct; 39(6):647-63. PubMed ID: 23290320 [TBL] [Abstract][Full Text] [Related]
11. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Gao S; Ye H; Gerrin S; Wang H; Sharma A; Chen S; Patnaik A; Sowalsky AG; Voznesensky O; Han W; Yu Z; Mostaghel EA; Nelson PS; Taplin ME; Balk SP; Cai C Clin Cancer Res; 2016 Jul; 22(14):3672-82. PubMed ID: 26936914 [TBL] [Abstract][Full Text] [Related]
12. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further. Fujimoto N J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726 [TBL] [Abstract][Full Text] [Related]
13. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model. Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550 [TBL] [Abstract][Full Text] [Related]
14. GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression. Cucchiara V; Yang JC; Liu C; Adomat HH; Tomlinson Guns ES; Gleave ME; Gao AC; Evans CP Mol Cancer Ther; 2019 Oct; 18(10):1811-1821. PubMed ID: 31341032 [TBL] [Abstract][Full Text] [Related]
15. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer. Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864 [TBL] [Abstract][Full Text] [Related]
16. Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions. Isaacsson Velho P; Carducci MA Expert Opin Investig Drugs; 2018 Oct; 27(10):811-822. PubMed ID: 30118330 [TBL] [Abstract][Full Text] [Related]
17. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Coutinho I; Day TK; Tilley WD; Selth LA Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360 [TBL] [Abstract][Full Text] [Related]
18. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer. Thamilselvan V; Menon M; Thamilselvan S Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552 [TBL] [Abstract][Full Text] [Related]
19. Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor. Montagnani Marelli M; Manea M; Moretti RM; Marzagalli M; Limonta P Int J Oncol; 2015 Jan; 46(1):243-53. PubMed ID: 25351635 [TBL] [Abstract][Full Text] [Related]
20. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. Martin SK; Kyprianou N Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]